FXR agonists for NASH: How are they different and what difference do they make?

J Hepatol. 2021 Jul;75(1):12-15. doi: 10.1016/j.jhep.2021.03.020. Epub 2021 May 10.

Author

Claus Kremoser¹

Affiliation

¹ Phenex Pharmaceuticals AG, Heidelberg, Germany. Electronic address: claus.kremoser@phenex-pharma.com.

PMID: 33985820
DOI: 10.1016/j.jhep.2021.03.020

No abstract available

Keywords: Cilofexor; EDP-305; FXR agonist; MET-409; NASH; Obeticholic acid; Tropifexor; histopathology; liver fibrosis; pruritus.

Publication types

Editorial
Comment

MeSH terms

Chenodeoxycholic Acid
Humans
Non-alcoholic Fatty Liver Disease* / drug therapy
Receptors, Cytoplasmic and Nuclear

Substances

Receptors, Cytoplasmic and Nuclear
Chenodeoxycholic Acid